biostudies-literatureUnknown64(12)Chen L⁶⁸Ga-labeled fibroblast activation protein inhibitor (⁶⁸Ga-FAPI) PET/CT has demonstrated promising clinical results, with a higher SUV_max and tumor-to-background ratio (TBR) in breast cancer (BC) patients than ¹⁸F-FDG PET/CT. Here, we aimed to evaluate the suitability of ⁶⁸Ga-FAPI PET/CT for the early and late prediction of the pathologic response to neoadjuvant chemotherapy (NAC) in BC. <b>Methods:</b> Twenty-two consecutive patients with newly diagnosed BC and an indication for NAC were prospectively included. All patients underwent standard chemotherapy and ⁶⁸Ga-FAPI PET/CT at baseline, after 2 cycles of NAC (PET2), and 1 wk before surgery (PET3). SUV_max was measured in the primary tumor region and positive regJournal of nuclear medicine : official publication, Society of Nuclear Medicine1899-1905https://www.ebi.ac.uk/biostudies/studies/S-EPMC10690122biostudies-literature⁶⁸Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study.PMC10690122Wu KKong LZhu YChen LZheng SXu SChen XMiao WXue Jfalse⁶⁸Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study.⁶⁸Ga-labeled fibroblast activation protein inhibitor (⁶⁸Ga-FAPI) PET/CT has demonstrated promising clinical results, with a higher SUV_max and tumor-to-background ratio (TBR) in breast cancer (BC) patients than ¹⁸F-FDG PET/CT. Here, we aimed to evaluate the suitability of ⁶⁸Ga-FAPI PET/CT for the early and late prediction of the pathologic response to neoadjuvant chemotherapy (NAC) in BC. <b>Methods:</b> Twenty-two consecutive patients with newly diagnosed BC and an indication for NAC were prospectively included. All patients underwent standard chemotherapy and ⁶⁸Ga-FAPI PET/CT at baseline, after 2 cycles of NAC (PET2), and 1 wk before surgery (PET3). SUV_max was measured in the primary tumor region and positive reg2023-01-01T00:00:00Z2023 Dec2025-04-25T17:37:01.869Z2025-04-06T04:05:29.869ZS-EPMC106901223791886610.2967/jnumed.123.266079